
    
      In this study, open-label dutogliptin/PHX1149T will be offered to subjects who complete a
      Phase 3 core protocol and wish to continue treatment with dutogliptin. This will allow for
      the collection of long-term safety data and will also demonstrate long-term effects on HbA1c
      and fasting blood glucose.
    
  